Literature DB >> 20350161

Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia.

Nicola E Mackie1, Andrew N Phillips, Steve Kaye, Clare Booth, Anna-Maria Geretti.   

Abstract

This study characterized the prevalence and patterns of antiretroviral-drug-resistance mutations according to plasma human immunodeficiency virus type 1 (HIV-1) RNA load in a large population of patients with HIV-1 infection who underwent testing for resistance mutations in routine clinical practice. HIV-1 genotypic resistance test results with linked clinical data were obtained from national resistance and clinical databases in the United Kingdom. Among 7861 tests, detection of > or =1 resistance mutation was most frequent at viral loads of 300-10,000 copies/mL and decreased statistically significantly at viral loads of >10,000 copies/mL. Major resistance mutations were commonly detected in the subset of tests that were performed among patients with viral loads of <1000 copies/mL (1001 [12.7%] of 7861 tests). We conclude that HIV-1 genotypic resistance testing is informative for patients with low viral loads.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20350161     DOI: 10.1086/651618

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia.

Authors:  Jonathan Z Li; Sebastien Gallien; Tri D Do; Jeffrey N Martin; Steven Deeks; Daniel R Kuritzkes; Hiroyu Hatano
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

2.  HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure.

Authors:  Luke C Swenson; Jeong Eun Min; Conan K Woods; Eric Cai; Jonathan Z Li; Julio S G Montaner; P Richard Harrigan; Alejandro Gonzalez-Serna
Journal:  AIDS       Date:  2014-05-15       Impact factor: 4.177

3.  International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK.

Authors: 
Journal:  J Int AIDS Soc       Date:  2016-10-23       Impact factor: 5.396

Review 4.  Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings.

Authors:  Mina C Hosseinipour; Ravindra K Gupta; Gert Van Zyl; Joseph J Eron; Jean B Nachega
Journal:  J Infect Dis       Date:  2013-06-15       Impact factor: 5.226

5.  Prevalence of sexually acquired antiretroviral drug resistance in a community sample of HIV-positive men who have sex with men in New York City.

Authors:  Lloyd A Goldsamt; Michael C Clatts; Monica M Parker; Vivian Colon; Renee Hallack; Maria G Messina
Journal:  AIDS Patient Care STDS       Date:  2011-04-02       Impact factor: 5.078

6.  Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy.

Authors:  Babafemi Taiwo; Sebastien Gallien; Evgenia Aga; Heather Ribaudo; Richard Haubrich; Daniel R Kuritzkes; Joseph J Eron
Journal:  J Infect Dis       Date:  2011-08-15       Impact factor: 5.226

7.  Persistent Low-level Viremia While on Antiretroviral Therapy Is an Independent Risk Factor for Virologic Failure.

Authors:  Christie Joya; Seung Hyun Won; Christina Schofield; Tahaniyat Lalani; Ryan C Maves; Karl Kronmann; Robert Deiss; Jason Okulicz; Brian K Agan; Anuradha Ganesan
Journal:  Clin Infect Dis       Date:  2019-11-27       Impact factor: 9.079

8.  Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.

Authors:  Patrick Ryscavage; Sean Kelly; Jonathan Z Li; P Richard Harrigan; Babafemi Taiwo
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

9.  First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.

Authors:  Abdel Babiker; Hannah Castro nee Green; Alexandra Compagnucci; Susan Fiscus; Carlo Giaquinto; Diana M Gibb; Lynda Harper; Linda Harrison; Michael Hughes; Ross McKinney; Ann Melvin; Lynne Mofenson; Yacine Saidi; M Elizabeth Smith; Gareth Tudor-Williams; A Sarah Walker
Journal:  Lancet Infect Dis       Date:  2011-01-31       Impact factor: 25.071

10.  High Prevalence of NRTI and NNRTI Drug Resistance Among ART-Experienced, Hospitalized Inpatients.

Authors:  Claire Bossard; Birgit Schramm; Stephen Wanjala; Lakshmi Jain; Gisèle Mucinya; Valarie Opollo; Lubbe Wiesner; Gilles van Cutsem; Elisabeth Poulet; Elisabeth Szumilin; Tom Ellman; David Maman
Journal:  J Acquir Immune Defic Syndr       Date:  2021-07-01       Impact factor: 3.771

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.